QLGN: Qualigen Corp Company Value to Net Income

Qualigen Corp - graphic logo of issuer QLGN

This daily price chart for Qualigen Therapeutics (QLGN) on the GURU.Markets platform reflects a value of -1.20. The business relies on FastPack AI platforms for the automated discovery of biomarkers without human intervention. However, geopolitical fragmentation and trade barriers are reducing export revenues. Consequently, management is cutting ancillary projects, redirecting available funds toward the development of its oncology profile.

QLGN - Qualigen Therapeutics, Inc. P/E Multiple over the range 07/04/2022 - 11/19/2025

Analytical breakdowns for Qualigen (QLGN)

- price and consensus price forecast:
Stock Price qualigeninc.com|QLGN - Consensus Target
- market capitalization information:
Market Value Qualigen Therapeutics, Inc.|QLGN - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Net Assets per Single Share Qualigen Therapeutics|QLGN - Book Capitalization|Market Capitalization to Book Value qualigeninc.com|QLGN - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Qualigen Therapeutics|QLGN - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Qualigen Corp|QLGN - Company Debts|Debts to Net Assets Qualigen Therapeutics, Inc.|QLGN - Company Long-Term Debt|Short-Term Indebtedness Qualigen Therapeutics|Quick Ratio qualigeninc.com
- earnings and market ratios statistics:
QLGN - Net Profit|Projected Future Earnings Qualigen Therapeutics|QLGN - Price to Earnings Ratio|Future Price to Earnings Qualigen Therapeutics Inc|QLGN - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Qualigen Therapeutics, Inc.|QLGN - Operating profit EBITDA|Net earnings per share for the trailing year Qualigen Therapeutics|QLGN - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months qualigeninc.com|QLGN - Earnings per share growth in current year|Projected earnings per share growth rate for next year Qualigen Therapeutics
Comprehensive company analysis:Qualigen Therapeutics
Flagship merchandise of Qualigen

The P/E ratio determines the cost of one unit of net profit, reflecting market expectations for the asset's return. By analyzing the estimated P/E of a company, an investor can discern actual capital density and overvaluation risks. The metric is calculated as the ratio of the current share price to the annual earnings per share. For Qualigen Therapeutics (QLGN), this trend is critical, as the business focuses on costly oncology developments. High values here typically reflect the market's confidence in the future commercialization of innovative diagnostic platforms.

Analysis of competing companies

P/E Multiple gilead.com|Price to Earnings Ratio CDTX (Cidara Corp)|NVAX (Novavax Inc) - Company Value to Net Income|CureVac Corp - Price to Earnings Ratio|Valneva Vaccines - Price to Earnings Ratio|Vir Biotechnology, Inc. - P/E Multiple|Business Payback Period siga.com SIGA|Emergent BioSolutions Inc. (EBS) - Price to Earnings Ratio|Atea Pharma - Company Value to Net Income|Price to Earnings Ratio IVVD|P/E Multiple Enanta Pharmaceuticals, Inc|Price to Earnings Ratio Inovio Pharmaceuticals (INO)|Business Payback Period hillevax.com|Price to Earnings Ratio Kalaris Therapeutics KLRS|Market Cap to Net Income Ratio Dyadic International Inc|NNVC: Price to Earnings Ratio|TLPH - P/E Multiple|COCP: P/E Multiple|Traws Pharma (TRAW) - P/E Multiple|Price to Earnings Ratio Dogwood Therapeutics Inc.|Price to Earnings Ratio ALVR|P/E Multiple VBIV|Business Payback Period virios.com|P/E Multiple VXRT (Vaxart)